AVTX (Avalo Therapeutics) EPS without NRI: $-4.81 (TTM As of Mar. 2026)


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $17.79
GF Value $0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics EPS without NRI?

Avalo Therapeutics AVTX +2.86% 23 EPS without NRI is $-4.81 as of Mar. 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,171 Biotechnology companies, Avalo Therapeutics ranks better than 95.99% on this metric.

Avalo Therapeutics's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.99. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.81.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 82.90% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 72.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Avalo Therapeutics's EPS without NRI or its related term are showing as below:

AVTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -20.6   Med: 37.7   Max: 82.9
Current: 82.9

During the past 13 years, Avalo Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 82.90% per year. The lowest was -20.60% per year. And the median was 37.70% per year.

AVTX's 3-Year EPS without NRI Growth Rate is ranked better than
95.99% of 1171 companies
in the Biotechnology industry
Industry Median: 16.8 vs AVTX: 82.90

Avalo Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.98. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.46.

Avalo Therapeutics's EPS (Basic) for the three months ended in Mar. 2026 was $-0.98. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.46.


Avalo Therapeutics  (NAS:AVTX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Avalo Therapeutics EPS without NRI Related Terms


Avalo Therapeutics EPS without NRI Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics EPS without NRI Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,388.00 -1,063.00 -100.42 -21.18 -5.28

Avalo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.28 -1.74 -1.48 -0.59 -0.99

AVTX vs SANA, ANRO, REPL: EPS without NRI Comparison

For the Biotechnology subindustry, Avalo Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's PE Ratio without NRI falls into.


AVTX
23GF Score
Avalo Therapeutics Inc AVTX
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-4.81 mean?
Avalo Therapeutics (AVTX) has a EPS without NRI of $-4.81 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Avalo Therapeutics and its competitors. According to the industry distribution chart, Avalo Therapeutics ranks #47 out of 1171 companies in the Biotechnology industry, placing it in the top 4%.
Is Avalo Therapeutics' EPS without NRI too high?
Avalo Therapeutics' current EPS without NRI is $-4.81. Based on the distribution chart, Avalo Therapeutics ranks #47 out of 1171 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' EPS without NRI compare to SANA and ANRO?
According to the Biotechnology industry distribution chart, Avalo Therapeutics ranks #47 out of 1171 companies for EPS without NRI. This places Avalo Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Avalo Therapeutics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalo Therapeutics's current EPS without NRI is $-4.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $17.79 — trading 59200% above its estimated fair value. The current EPS without NRI is $-4.81. Avalo Therapeutics' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current EPS without NRI is $-4.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $17.79 is trading 59200% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • EPS without NRI: $-4.81
  • GF Value™: $0.03 vs. price of $17.79 (59200% above fair value)
  • GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.79
Price
$0.03
GF Value